BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. Show more

680 W. Nye Lane, Carson City, NV, 89703, United States

Biotechnology

Healthcare

Market Cap

18.51M

52 Wk Range

$0.82 - $3.79

Previous Close

$2.19

Open

$2.20

Volume

485,693

Day Range

$2.11 - $2.25

Enterprise Value

9.891M

Cash

13.1M

Avg Qtr Burn

-7.442M

Insider Ownership

0.30%

Institutional Own.

19.78%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bezisterim (NE3107) Details Alzheimer's disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BIV201 Details Ascites	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezisterim (NE3107) Details Early Parkinson's disease	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bezisterim (NE3107) Details Neurological symptoms associated with long COVID	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.